US EditionBlueRock Initiates First Human Trial of iPSC Cell Therapy for Retinal Diseases
Summary by healtheconomics.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
BlueRock Initiates First Human Trial of iPSC Cell Therapy for Retinal Diseases
BlueRock Therapeutics, a Bayer subsidiary, has launched the CLARICO trial, marking the first clinical study of an induced pluripotent stem cell (iPSC)-derived therapy for primary photoreceptor diseases, such as retinitis pigmentosa and cone-rod dystrophy. The Phase I/II trial will assess the safety, tolerability, and efficacy of OpCT-001 in approximately 54 adults, focusing initially on safety through a dose-escalation design before evaluating v…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium